Gene therapy breakthrough offers hope for rare brain disease
NCT ID NCT04833907
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a single dose of AVASPA gene therapy given directly into the brain of children with Canavan disease, a rare and severe genetic disorder that damages white matter. The therapy aims to restore a missing enzyme to help the brain produce myelin and slow disease progression. Up to 24 children will be enrolled across three age groups to evaluate safety and early signs of benefit.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AVASPA gene therapy (MYR-101)
What this could lead to
If successful, this could provide a treatment that slows or stops the progression of Canavan disease, improving quality of life and extending survival for affected children.
What could go wrong
This is an early-phase trial with only 24 participants, so results may not apply to all. Gene therapy carries risks like immune reactions or surgical complications, and long-term effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANAVAN DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dayton Children's Hospital
Dayton, Ohio, 45404, United States